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Abstract
As more human immunodeficiency virus (HIV)–infected patients access combination antiretroviral therapy
(cART), higher proportions of newly infected patients may be infected with drug-resistant viruses. Regular
surveillance of transmitted drug resistance (TDR) is required in southern Africa where high rates of trans-
mission persist despite rapid expansion of ART. Dried blood spot samples from cART-naive participants from
two rounds of an annual population-based HIV surveillance program in rural KwaZulu-Natal were tested for
HIV RNA, and samples with HIV RNA >10,000 copies/ml were genotyped for drug resistance. The 2009
surveillance of drug resistance mutation (SDRM) list was used for drug resistance interpretation. The data were
added to previously published data from the same program, and the w2 test for trend was used to test for trend in
estimated prevalence of any TDR. Seven hundred and one participants’ data were analyzed: 67 (2010), 381
(2011), and 253 (2012). No TDR was detected in 2010. Years 2011 and 2012 had 18 participants with SDRMs
4.7% and 7.1%, respectively ( p= .02, w2 test for trend). The nonnucleoside reverse transcriptase inhibitor
mutation, K103N, was the most common mutation, occurring in 27 (3.8%) of the participants, while nucleoside
reverse transcriptase inhibitor (NRTI) SDRMs were detected in 10 (1.4%) of the participants, of whom eight
had only a single NRTI SDRM. The increase in levels of drug resistance observed in this population could be a
signal of increasing transmission of drug-resistant HIV. Thus, continued surveillance is critical to inform public
health policies around HIV treatment and prevention.
Introduction
Antiretroviral therapy (ART) has been the mostimportant weapon in the control of the human immu-
nodeficiency virus type 1 (HIV-1) epidemic to date. Com-
bination ART (cART) for the management of HIV-infected
patients has been associated with a reduction in morbidity
and mortality as well as in HIV-1 incidence.1 Currently, HIV
treatment guidelines are moving from the use of cART to
prevent individual morbidity and mortality toward the use of
cART as part of a comprehensive package of prevention
under the test-and-treat programs.2 It is hoped that successful
cART in a population will significantly reduce HIV incidence
and turn the tide on the epidemic.1
The development and transmission of antiretroviral drug
resistance have the potential to compromise the effectiveness
of standardized regimens used in the public health approach
to ART. In most high-income settings in Europe and North
America, drug resistance monitoring has been integrated into
the continuum of care of patients to provide better optimized
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ART. Their treatment guidelines recommend drug resistance
testing for patients before ART initiation and at the time of
virological failure.3–5 In low- and middle-income countries, a
population-based approach to drug resistance is currently
being implemented. The World Health Organization (WHO)
currently recommends a series of surveillance and monitor-
ing programs for transmitted drug resistance (TDR)6 and
acquired drug resistance,7,8 respectively. There have been
many changes in the surveys, and there is still no consensus
on the best surveillance approach for TDR. The previous
approach focused on identifying individuals likely to be re-
cently infected to accurately determine the burden of TDR in
the treatment programs. However, the most recent recom-
mendations focus on the surveillance of pretreatment HIV
drug resistance (HIVDR) in ART-naive populations,9 which
directly assesses the effectiveness of the standard first-line
regimens on the populations initiating therapy.
A number of studies have reported the levels and patterns
of TDR in different South African provinces among different
population groups using the WHO surveys.10 Most studies
have been conducted among young pregnant women acces-
sing antenatal services. Primary drug resistance has been
generally less than 5% inmost parts of South Africa, except in
KwaZulu-Natal. Two independent studies in KwaZulu-Natal
showed intermediate levels of TDR (5%–15%) from patients
recruited in 2009 and 2010.10,11 However, two other studies
also done during the same years did not find any evidence of
TDR in the province.12,13 Furthermore, most of these studies
had limited information on the duration of the infections, and
most had small sample sizes that limited the precision of the
estimates. A global meta-analysis of the WHO TDR surveys
showed a statistically significant increase in TDR levels in
East Africa where the epidemic is more mature and the ART
programs are longer but not in southern Africa.14
The primary aim of this study was to determine whether
there was evidence of an increase in TDR within a demo-
graphic surveillance area with documented high HIV inci-
dence and good ART coverage in rural KwaZulu-Natal. In
addition, we assessed the difference in the levels of drug
resistance between recently and chronically infected indi-
viduals and explored the utility of different definitions of
recent infection to guide future surveillance programs.
Methods
The study used samples collected from a population-based
HIV surveillance conducted in 2011 and 2012 in KwaZulu-
Natal, South Africa. These were follow-up studies to our
previous report of TDR.13 The Africa Centre for Health and
Population Studies (Africa Centre) has conducted longitu-
dinal population-based HIV surveillance in the rural district
of uMkhanyakude in northern KwaZulu-Natal since 2003.
Adult (15–49 years) HIV prevalence in 2011 was 29%,15 and
crude HIV incidence was 2.63 per 100 person-years between
2004 and 2011 for all adults older than 15 years.1 There has
been a rapid expansion of ART coverage in the area since
2004, with an estimated 37% of all HIV-infected adults on
ART in July 2011.1 HIV treatment and care is delivered
through a decentralized primary health care program in ac-
cordance with the National Department of Health guidelines.
HIV-1 viral load tests were done on all dried blood spot
samples that tested positive by serology (SD Bioline ELISA,
Yongin, South Korea) for HIV-1 during the 2011 and 2012
surveillance rounds. Only samples from cART-naive partic-
ipants with viral loads greater than 10,000 RNA copies/ml
were genotyped. For participants with more than one sample
during the study period, only the earliest sample was used for
analysis. For viral load determination, HIV-1 RNA was ex-
tracted using an automated platform, the NucliSENS easy-
Mag (BioMerieux, Marcy-l¢E´toile, France), with an elution
volume of 50 ll. An aliquot of the same RNA extract was
used for HIV-1 drug resistance genotyping within 6 hours of
extraction. The previously described SATuRN/Life Tech-
nologies genotyping system was used for genotyping.13,16
Previously published sequences from 2010 were also used
in this analysis.13 The data from 2010 were generated from
plasma samples obtained from individuals with documented
evidence of recent seroconversion. Inclusion criteria for en-
rollment included a confirmed seropositive test in 2010,
preceded by an HIV-1–seronegative test in the previous
surveillance round in which the person had participated.13
Sequences covering all the 99 protease codons and the first
300 reverse transcriptase codons were assembled using Gen-
eious 8.0.3 software.17 Sequence quality was assessed using the
HIV-1 Quality Analysis Tool18 and the Calibrated Population
Resistance (CPR) tool.19 HIV-1 subtyping was performed us-
ing the REGA HIV-1 Subtyping Tool v 3.0.20 Phylogenetics
was used to rule out intralaboratory contamination among the
samples. The 2009 surveillance of drug resistance mutation
(SDRM) list was used in the TDR analysis.21,22
The estimated date of HIV infection was calculated as the
midpoint between the last negative test date and the first
positive test date for cases where both these were known. The
estimated duration of infection (months) was determined by
calculating the time between the estimated date of infection23
and sample date. Participants with an estimated duration of
infection £24 months were classified as recent infections.
More stringent and more relaxed definitions of recent infec-
tion, £12 and £36 months, respectively, were used to assess
the ability to accurately determine the levels of TDR at dif-
ferent periods after infection. TDR levels were assessed for
both 2011 and 2012.
Summary statistics were calculated using Stata 10 (Stata-
Corp, College Station, TX). Confidence intervals for pro-
portions were estimated using the exact binomial method.
The proportions of samples with any drug resistance mutation
were compared for the years 2010, 2011, and 2012 using the
w2 test for trend. Logistic regression analysis was used to
identify predictors of DRM. The model was fitted using the
generalized linear model function in the R open software
statistical environment version 3.2.0 with resistance status,
having any DRM versus no DRM as the outcome of interest
and time as the independent variable. The w2 test was used to
compare the proportion of participants with DRM by esti-
mated duration of infection. For continuous variables, such as
viral load, the Student’s t-test was used.
Individual-level data from the surveillance program were
linked to data from the HIV treatment program database to
identify individuals who had received ART before the date of
genotype. These individuals were excluded from the analysis.
The program database contains detailed information on cART
regimens but not on prevention of mother-to-child transmis-
sion (pMTCT) regimens. For female participants with evi-
dence of drug resistance mutations, data on pregnancies were
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merged from the demographic surveillance system to ascer-
tain potential exposure to antiretrovirals for pMTCT. Poten-
tial exposure to pMTCT regimen was considered if a
pregnancy occurred after the last negative surveillance HIV
test (or after 2002 for those with no negative surveillance test)
and before the sample date.
Ethics Statement
Ethics permission for the population-based HIV surveil-
lance at the Africa Centre and for the linkage to routine health
system records about ARTwas obtained from the Biomedical
Research Ethics Committee of the College of Health Sci-
ences, University of KwaZulu-Natal (Ethics Nos. BF233/09
and E134/06). All participants in the study provided written
informed consent for the analysis of their samples.
Results
Data presented in this study include previously published
data from 2010 and new data from 2011 and 2012. From the
2011 and 2012 surveillance rounds, 2,459 and 1,977 samples,
respectively, tested positive. Table 1 summarizes the num-
bers of samples tested. Eventually, including the 2010 sam-
ples, 799 sequences were available for use in this analysis.
Fifty-three of these were excluded because they were from
participants exposed to cART. Forty-five participants had
more than one sequence frommultiple surveillance years. No
sequences were identified as contaminants. Therefore, a total
of 701 participants’ data were used in this analysis. Sixty-
seven, 381, and 253 were from the 2010, 2011, and 2012
surveillance rounds, respectively (Supplementary Fig. 1;
Supplementary Data are available online at www.liebertpub
.com/aid).
Using the estimated duration of infection of £24 months to
define recently infected participants, there were 134 individ-
uals identified as recently infected. Their mean estimated
duration of infectionwas 13months (standard deviation [SD]:
6). Men constituted 25% of all the participants. The mean age
was 34 years (SD: 12). The mean viral load for the 2011 and
2012 participants was 5.1 log10 RNA copies/ml (SD: 0.7).
There were no statistically significant differences in sex, age,
viral load (2011 and 2012 only), and estimated duration of
infection between the three sampling years (Table 2).
All the genotyped samples were HIV-1 subtype C. One or
more DRMs were identified in 36 (5.1%) of the 701 par-
ticipants. Of these, the non-nucleoside reverse transcriptase
inhibitor (NNRTI) resistance mutations were the most preva-
lent, detected in 32 (4.6%) of the participants. Of these, the
most common were K103N, V106M, and G190A occurring in
27 (3.9%), 3 (0.4%), and 2 (0.3%) participants, respectively.
Nucleoside reverse transcriptase inhibitor (NRTI) SDRMs
were detected in 10 (1.4%) of the participants, of whom eight
had only one NRTI SDRM. Six (0.9%) participants had both
NNRTI and NRTI resistance mutations, K103N+M184V be-
ing the most common combination. Of those with NRTI mu-
tations, five (0.7%) had only the M184Vmutation, two (0.3%)
had the K65R mutation alone, one (0.1%) had the M41L
mutation alone, and two (0.3%) had multiple thymidine ana-
loguemutations (onewithM184V). There were no statistically
significant differences between the proportion that were men,
the ages, the median viral load, and the estimated duration of
infection between the participants who had evidence of TDR
and those who had wild-type viruses.
Table 1. Summary of the Samples Tested
Between 2011 and 2012 Leading to the HIV
Drug Resistance Genotyping
2011 2012
DBS samples tested for HIV serology 10,388 7,919
DBS samples tested positive 2,459 1,977
DBS tested for RNA viral load 2,419 1,494
DBS samples with viral load >10,000
copies/ml
1,079 650
Samples genotyped for drug resistance 875 587
Samples successfully amplified 452 303
Samples successfully sequenced 439 289
DBS, dried blood spot; HIV, human immunodeficiency virus.
Table 2. Summary of the Characteristics of the Surveillance Participants Included
in the Analysis from the Three Sampling Years
Total 2010a 2011 2012 p-Valuesb
Participants, n 701 67 381 253
Men, n (%) 176 (25) 10 (15) 93 (24) 73 (29) .058
Age, mean (SD), years 34 (12) 29 (9) 34 (12) 34 (13) .002
Viral load, log10 copies/ml, mean (SD) 5.1 (0.6) — 5.0 (0.3) 5.1 (0.4) .1146
Estimated duration of infection, mean (SD), monthsc 30 (21) 28 (16) 29 (20) 34 (26) .2026
Number with recent infection according to different thresholds, n (%), months
£12 79 (11) 17 (25) 37 (10) 25 (10) .001
£24 134 (19) 30 (45) 68 (18) 36 (14) <.001
£36 179 (26) 44 (66) 91 (23) 44 (17) <.001
aThe World Health Organization minimal sequential sampling strategy was used for 2010. The focus was to genotype recently infected
individuals identified through seroconversion in serial testing in an annual population-based HIV surveillance.
bv2 p-values. For viral load, a t-test comparing group means was used.
cThis is an estimate of how long the participant has been infected with HIV based on the data available. It was determined by subtracting
the midpoint between the last known negative and the first known positive from current sampling date (Supplementary Fig. 2). Not all
patients had a previous negative test. The numbers of patients with a previous documented negative result were 65, 136, and 75 for the years
2010, 2011, and 2012, respectively.
SD, standard deviation.
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There was no evidence of SDRM from the 67 samples
collected in 2010. Years 2011 and 2012 had 18 participants
with any SDRM, 4.7% (95% confidence interval (CI): 2.8%–
7.4%) and 7.1% (95% CI: 4.3%–11.0%), respectively
( p = .02, w2 test for trend). This was confirmed through lo-
gistic regression or equivalently a generalized linear model
with time as a predictor variable, which yielded a significant
time effect with the same p-value of .02. However, there was
no statistically significant difference between 2010 and 2011
( p = .07, w2 test) or 2011 and 2012 ( p = .20, w2 test, Figure 1).
There were no clear differences in the patterns of mutations
between 2011 and 2012, with NNRTImutations dominant for
both years.
The proportions of any SDRM were not significantly dif-
ferent between recently infected participants (infected within
24months of sampling), chronically infected participants, and
participants with unknown duration of infections, 7% (95%
CI: 3%–12%), 4% (95% CI: 2%–6%), and 7% (95% CI: 3%–
12%), respectively. The two other definitions of recent infec-
tion (£12 and £36 months) produced similar results (Table 3).
Of the 30 females with drug resistance mutations, 15 had at
least one pregnancy between their last negative surveillance
HIV test and the sample date or between 2002 and the sample
date (for those without a prior negative surveillance HIV
test). Twelve of the 15 had a single NNRTI mutation (10 with
K103N, 1 with V106M, and 1 with G190A) (Supplementary
Table S1.
Discussion
The Africa Centre Demographic Surveillance Area (DSA)
provides a rare environment to assess the impact of increas-
ing treatment coverage on TDR; ART coverage has increased
rapidly for the past 10 years.1,24 However, regardless of the
high ART coverage, the area still has one of the highest HIV
incidence rates in South Africa.1,25 High levels of acquired
resistance among patients failing therapy have also been re-
ported from the subdistrict.26 A longitudinal population-
based HIV surveillance program and the ability to merge data
from a large public sector HIV treatment program provide the
ideal opportunity for surveillance of TDR at population level.
Our findings of increasing levels of drug resistance in cART-
naive adults in 2011 and 2012 could be a signal of the
transmission of drug-resistant HIV in the population. The
major limitation of our analysis is that, despite our ability to
merge data on cART exposure, no data were available re-
garding antiretroviral exposure for pMTCT. Half of the fe-
males with evidence of drug resistance had potential
exposure to antiretrovirals for pMTCT based on documen-
tation of pregnancy before the date of genotypic resistance
testing. Nevertheless, the levels of drug resistance give cause
for some concern and highlight the need for robust drug re-
sistance surveillance systems during this time of rapidly ex-
panding ART access.
This study was a follow-up to data published from samples
collected from the 2010 surveillance round.13 There is evi-
dence of TDR in 2011 and 2012, which was not present with a
much smaller study population in 2010. With no evidence of
TDR in 2010, there seems to be an increasing trend in TDR,
although the sample size was small in 2010. However, there is
no statistically significant evidence of an increase in TDR
between 2011 and 2012. Nonetheless, the increase in TDR in
the DSA between 2010 and 2012 is consistent with other re-
ports from the KwaZulu-Natal10,11 as well as Uganda, Zambia,
and other settings that have reported intermediate to high
levels of TDR in areas of high ART coverage.27–29
The results of the comparison between recent and chronic
infections could be important in the design of new surveil-
lance programs. However, the results need to be confirmed
from samples with more representation of recently infected
participants. This would provide better statistical power to
detect smaller differences in resistance levels between re-
cently infected and chronically infected treatment-naive
participants. The mutations contributing to most of the
Table 3. Proportion of Participants with Surveillance Drug Resistance Mutations
According to Three Different Definitions of Recent Infections
Definition of
recent infections
Proportion with
SDRM in recently
infected, % (n)
Proportion with
SDRM in chronically
infected, % (n)
Proportion with SDRM
in patients with unknown
duration infection, % (n) p-Valuea
£12 months
All 8 (79) 4 (472) 7 (150) .289
2010 0 (17) 0 (50) — —
2011 11 (37) 4 (263) 5 (81) .169
2012 8 (25) 6 (159) 9 (69) .797
£24 months
All 7 (134) 4 (417) 7 (150) .306
2010 0 (30) 0 (37) — —
2011 9 (68) 3 (232) 5 (81) .133
2012 8 (36) 7 (148) 7 (69) .748
£36 months
All 6 (179) 4 (372) 7 (150) .515
2010 0 (44) 0 (23) — —
2011 7 (91) 4 (209) 5 (81) .580
2012 9 (44) 4 (140) 9 (69) .626
av2 p-values.
CI, confidence interval; DSA, demographic surveillance area; SDRM, surveillance of drug resistance mutation.
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resistance in 2011 and 2012 were the NNRTI mutations,
specifically K103N has been shown to persist in plasma for as
long as 3 years in primary infection.30,31 Other mutations,
especially the thymidine analogue mutations (TAMs) and
TAM revertants, can persist for even longer periods.31 Thus,
it may not be necessary to distinguish between recently in-
fected and chronically infected participants in the assessment
of TDR.
There were a few noteworthy examples of drug resistance
from the 2011 and 2012 participants. The first was a male
individual infected with a virus with multiclass resistance
(NNRTI+NRTI), including two TAMs (D67N and K219Q)
and the T215 revertant (T215A). This participant had his last
negative test in January 2010 and the first positive test in
January 2011, with an estimated duration of infection of 6
months. With that time frame, the patient would also have
been expected to have the M184V mutation in addition to the
three NRTI mutations. However, the reduced fitness associ-
ated with the M184Vmutation might have resulted in the fast
reversion to wild type at this codon, if the transmitted virus
had the mutation. Alternatively, the person who transmitted
the virus may have interrupted treatment before the trans-
mission event, thus reducing the likelihood of transmitting
the M184V virus.
The second was a case of transmission of a virus with
M184V mutation plus five TAMs but with no NNRTI mu-
tations. This participant had been infected for more than 4
years at the time of sampling. There was no evidence that this
participant had received ART in the local treatment program.
However, we cannot exclude the possibility of the patient
having accessed ART through another ART provider outside
the area or possibly having shared antiretrovirals with another
person. The absence of NNRTI mutations in this participant
is somewhat unusual considering their pattern of NRTI mu-
tations.
From the 2012 samples, there were two cases of trans-
mission of the K65R mutation, which is selected for by te-
nofovir (TDF) and which had been introduced into first-line
regimens in South Africa 2 years earlier in 2010. Generally,
the prevalence of transmitted K65R mutants has been low in
settings with widespread exposure to tenofovir-containing
ART regimens.32 There have been reports of rapid emergence
of the K65Rmutation in patients failing TDF-based regimens
infected with subtype C viruses.33 It had been previously
shown that K65R emerges more frequently in subtype C
viruses due to a difference in the template nucleotide se-
quence.34 This is of major importance in high-incidence
settings, especially with renewed interest in preexposure
prophylaxis based on tenofovir as well as the use of treatment
as a prevention tool.
Although recently infected patients not on ART are ex-
pected to have viral loads >10,000 RNA copies/ml, the use of
genotyping methods with higher sensitivity below 10,000
RNA copies/ml will enhance the detection of cases of
transmitted M184V mutation, which has been shown to be
associated with lower viral loads.35 However, no significant
differences in viral load have been observed for other mu-
tations (both NNRTI and NRTI mutations) between partici-
pants with TDR and those with wild-type viruses.35–37
Recent advances in the sequencing technologies, specifi-
cally the application of ultradeep sequencing using next-
generation sequencing, can add value to better understand
TDR. This allows the detection of minority drug resistance
variants (<20% of the viral population) that are usually
missed when using the traditional population sequencing.
This could better shed more light on M184V TDR as well as
the TAM revertants.
Finally, treatment exposure for the participants could only
be verified through the public treatment program associated
with the DSA. If any of the patients accessed therapy in
public programs from other districts or from the private
sector, that information would not be captured, resulting in
overestimation of TDR.
Our results suggest that TDR is increasing in rural
KwaZulu-Natal. With current levels of TDR, the current
treatment recommendations are still appropriate. However,
there is need for more vigilance in the surveillance of TDR to
identify further increases that might impact on the choice of
the recommended first-line regimens and/or need for the
genotypic resistance testing before the initiation of ART.
Future statistical analyses that incorporate individual-to-
individual heterogeneity or are able to capture individual-
specific effects are recommended.
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